‘Is MDMA a Human Neurotoxin?’:Diverse Views from the Discussants
Neuropsychobiology 2000 DOI: 10.1159/000026669 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Symposium of expert opinions and review of empirical studies Peer reviewed |
|---|---|
| Topics | MDMA |
| Keywords | Hallucinogen Cognition Neurotoxicity Behavioral neuroscience |
| Citations | 27 |
| Key findings | Argues that while some experts question the evidence for MDMA neurotoxicity due to methodological weaknesses, new studies confirm cognitive and neurological deficits in Ecstasy users that persist after controlling for other drug use. |
Abstract
UNLABELLED: Every discussant at the Novartis symposium was invited to submit a 250-word abstract, giving their views upon the question: 'Is MDMA a human neurotoxin?'. These abstracts are presented here. They illustrate a wide range of viewpoints and opinions, as might be expected from experts in such diverse fields: animal neuroscience, human cognitive testing, police pathology laboratory, psychotherapeutic institute and psychiatric hospital. Some abstracts emphasized the methodological weaknesses of the human empirical data: the uncertain nature of 'Ecstasy' tablets, the reliance on self-report data, and the contributory factors of heat, dancing/exertion, poor diet and other illicit drugs. These factors may lead to psychobiological changes, which could be misinterpreted as neural damage. The absence of gliosis in animal models was also noted, which led to suggestions that there might be alternative interpretations for the neural changes which have been observed in rats and monkeys. Others noted the absence of neural/behavioural change following a single Ecstasy tablet, or commented upon the therapeutic benefits of MDMA in a quiet supportive environment. Nevertheless, novel studies from England, Germany, Italy, the Netherlands, Scotland and Wales confirmed and extended the range of cognitive, behavioural, EEG and neurological deficits, displayed by drug-free Ecstasy users. Moreover, these deficits often remained when other illicit drug use was statistically controlled. IN CONCLUSION: If MDMA neurotoxicity in humans is a myth, then it is a myth with a heavy serotonergic component.
Comparable studies
Other narrative reviews on MDMA, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Human Pharmacology of MDMA | 2004 | Review | |
| Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research | 2001 | Review | |
| 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans | 1994 | Review | |
| (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals | 2000 | Review | |
| Amphetamine toxicities | 2010 | Review |
Citations in the library
Cited by 5
- Transient memory impairment after acute dose of 75mg 3.4-Methylene-dioxymethamphetamine Journal of Psychopharmacology November 1, 2005
- Psychedelic bliss : memory and risk taking during MDMA intoxication 2007
- Gender differences in hyperthermia and regional 5-HT and 5-HIAA depletion in the brain following MDMA administration in rats. Brain Research May 4, 2011
- Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug and Alcohol Dependence October 1, 2003
- Altered states: the clinical effects of Ecstasy. Pharmacology & Therapeutics April 2003
Cites 3
- Subjective Reports of the Effects of MDMA in a Clinical Setting Journal of Psychoactive Drugs October 1, 1986
- A Method of Conducting Therapeutic Sessions with MDMA Journal of Psychoactive Drugs December 1, 1998
- Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. Journal of Pharmacology and Experimental Therapeutics October 1, 1995